29 results on '"Angelsen, Jon-Helge"'
Search Results
2. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial
- Author
-
Aahlin, Eirik Kjus, Bratthäll, Charlotte, Halimi, Asif, Hatlevoll, Ingunn, Heby, Margareta, Kokkola, Arto, Kordes, Maximilian, Lindblad, Stina, Lundgren, Linda, Mortensen, Michael Bau, Mortensen, Kim Erlend, Persson, Jan, Rangelova, Elena, Rønne, Elin, Sandvik, Oddvar Mathias, Søreide, Jon Arne, Vilhav, Caroline, Waardal, Kim, Wennerblom, Johanna, Williamsson, Caroline, Yaqub, Sheraz, Labori, Knut Jørgen, Bratlie, Svein Olav, Andersson, Bodil, Angelsen, Jon-Helge, Biörserud, Christina, Björnsson, Bergthor, Bringeland, Erling Audun, Elander, Nils, Garresori, Herish, Grønbech, Jon Erik, Haux, Johan, Hemmingsson, Oskar, Liljefors, Maria Gustafsson, Myklebust, Tor Åge, Nymo, Linn Såve, Peltola, Katriina, Pfeiffer, Per, Sallinen, Ville, Sandström, Per, Sparrelid, Ernesto, Stenvold, Helge, Søreide, Kjetil, Tingstedt, Bobby, Verbeke, Caroline, Öhlund, Daniel, Klint, Leif, Dueland, Svein, and Lassen, Kristoffer
- Published
- 2024
- Full Text
- View/download PDF
3. Simultaneous Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: Contemporary Practice, Evidence and Knowledge Gaps
- Author
-
Kleive, Dyre, Aas, Eline, Angelsen, Jon-Helge, Bringeland, Erling A., Nesbakken, Arild, Nymo, Linn S., Schultz, Johannes K., Søreide, Kjetil, and Yaqub, Sheraz
- Published
- 2021
- Full Text
- View/download PDF
4. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1) : a multicentre, randomised, phase 2 trial
- Author
-
Labori, Knut Jørgen, Bratlie, Svein Olav, Andersson, Bodil, Angelsen, Jon-Helge, Biörserud, Christina, Björnsson, Bergthor, Bringeland, Erling Audun, Elander, Nils, Garresori, Herish, Grønbech, Jon Erik, Haux, Johan, Hemmingsson, Oskar, Gustafsson Liljefors, Maria, Myklebust, Tor Åge, Nymo, Linn Såve, Peltola, Katriina, Pfeiffer, Per, Sallinen, Ville, Sandström, Per, Sparrelid, Ernesto, Stenvold, Helge, Søreide, Kjetil, Tingstedt, Bobby, Verbeke, Caroline, Öhlund, Daniel, Klint, Leif, Dueland, Svein, Lassen, Kristoffer, Aahlin, Eirik Kjus, Bratthäll, Charlotte, Halimi, Asif, Hatlevoll, Ingunn, Heby, Margareta, Kokkola, Arto, Kordes, Maximilian, Lindblad, Stina, Lundgren, Linda, Mortensen, Michael Bau, Mortensen, Kim Erlend, Persson, Jan, Rangelova, Elena, Rønne, Elin, Sandvik, Oddvar Mathias, Søreide, Jon Arne, Vilhav, Caroline, Waardal, Kim, Wennerblom, Johanna, Williamsson, Caroline, Yaqub, Sheraz, Labori, Knut Jørgen, Bratlie, Svein Olav, Andersson, Bodil, Angelsen, Jon-Helge, Biörserud, Christina, Björnsson, Bergthor, Bringeland, Erling Audun, Elander, Nils, Garresori, Herish, Grønbech, Jon Erik, Haux, Johan, Hemmingsson, Oskar, Gustafsson Liljefors, Maria, Myklebust, Tor Åge, Nymo, Linn Såve, Peltola, Katriina, Pfeiffer, Per, Sallinen, Ville, Sandström, Per, Sparrelid, Ernesto, Stenvold, Helge, Søreide, Kjetil, Tingstedt, Bobby, Verbeke, Caroline, Öhlund, Daniel, Klint, Leif, Dueland, Svein, Lassen, Kristoffer, Aahlin, Eirik Kjus, Bratthäll, Charlotte, Halimi, Asif, Hatlevoll, Ingunn, Heby, Margareta, Kokkola, Arto, Kordes, Maximilian, Lindblad, Stina, Lundgren, Linda, Mortensen, Michael Bau, Mortensen, Kim Erlend, Persson, Jan, Rangelova, Elena, Rønne, Elin, Sandvik, Oddvar Mathias, Søreide, Jon Arne, Vilhav, Caroline, Waardal, Kim, Wennerblom, Johanna, Williamsson, Caroline, and Yaqub, Sheraz
- Abstract
Background In patients undergoing resection for pancreatic cancer, adjuvant modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improves overall survival compared with alternative chemotherapy regimens. We aimed to compare the efficacy and safety of neoadjuvant FOLFIRINOX with the standard strategy of upfront surgery in patients with resectable pancreatic ductal adenocarcinoma. Methods NORPACT-1 was a multicentre, randomised, phase 2 trial done in 12 hospitals in Denmark, Finland, Norway, and Sweden. Eligible patients were aged 18 years or older, with a WHO performance status of 0 or 1, and had a resectable tumour of the pancreatic head radiologically strongly suspected to be pancreatic adenocarcinoma. Participants were randomly assigned (3:2 before October, 2018, and 1:1 after) to the neoadjuvant FOLFIRINOX group or upfront surgery group. Patients in the neoadjuvant FOLFIRINOX group received four neoadjuvant cycles of FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, and fluorouracil 400 mg/m2 bolus then 2400 mg/m2 over 46 h on day 1 of each 14-day cycle), followed by surgery and adjuvant chemotherapy. Patients in the upfront surgery group underwent surgery and then received adjuvant chemotherapy. Initially, adjuvant chemotherapy was gemcitabine plus capecitabine (gemcitabine 1000 mg/m2 over 30 min on days 1, 8, and 15 of each 28-day cycle and capecitabine 830 mg/m2 twice daily for 3 weeks with 1 week of rest in each 28-day cycle; four cycles in the neoadjuvant FOLFIRINOX group, six cycles in the upfront surgery group). A protocol amendment was subsequently made to permit use of adjuvant modified FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2 over 46 h on day 1 of each 14-day cycle; eight cycles in the neoadjuvant FOLFIRINOX group, 12 cycles in the upfront surgery group). Randomisation was performed with a computerised algorithm that stratified for each pa, Correspondence to: Prof Knut Jørgen Labori, Department of Hepato Pancreato Biliary Surgery, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, N-0372 Oslo, NorwayFunding: Norwegian Cancer Society, South Eastern Norwegian Health Authority, The Sjöberg Foundation, and Helsinki University Hospital Research Grants.
- Published
- 2024
- Full Text
- View/download PDF
5. Practice patterns in diagnostics, staging, and management strategies of gallbladder cancer among Nordic tertiary centers
- Author
-
Takala, Sini, primary, Lassen, Kristoffer, additional, Søreide, Kjetil, additional, Sparrelid, Ernesto, additional, Angelsen, Jon-Helge, additional, Bringeland, Erling A., additional, Eilard, Malin S., additional, Hemmingsson, Oskar, additional, Isaksson, Bengt, additional, Karjula, Heikki, additional, Lammi, Jukka-Pekka, additional, Larsen, Peter N., additional, Lavonius, Maija, additional, Lindell, Gert, additional, Mortensen, Frank V., additional, Mortensen, Kim, additional, Nordin, Arno, additional, Pless, Torsten, additional, Sandström, Per, additional, Sandvik, Oddvar, additional, Vaalavuo, Yrjö, additional, Villard, Christina, additional, and Sallinen, Ville, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Practice patterns in diagnostics, staging, and management strategies of gallbladder cancer among Nordic tertiary centers
- Author
-
Takala, Sini, Lassen, Kristoffer, Soreide, Kjetil, Sparrelid, Ernesto, Angelsen, Jon-Helge, Bringeland, Erling A., Eilard, Malin S., Hemmingsson, Oskar, Isaksson, Bengt, Karjula, Heikki, Lammi, Jukka-Pekka, Larsen, Peter N., Lavonius, Maija, Lindell, Gert, Mortensen, Frank V., Mortensen, Kim, Nordin, Arno, Pless, Torsten, Sandström, Per A, Sandvik, Oddvar, Vaalavuo, Yrjo, Villard, Christina, Sallinen, Ville, Takala, Sini, Lassen, Kristoffer, Soreide, Kjetil, Sparrelid, Ernesto, Angelsen, Jon-Helge, Bringeland, Erling A., Eilard, Malin S., Hemmingsson, Oskar, Isaksson, Bengt, Karjula, Heikki, Lammi, Jukka-Pekka, Larsen, Peter N., Lavonius, Maija, Lindell, Gert, Mortensen, Frank V., Mortensen, Kim, Nordin, Arno, Pless, Torsten, Sandström, Per A, Sandvik, Oddvar, Vaalavuo, Yrjo, Villard, Christina, and Sallinen, Ville
- Abstract
Background and objective: Gallbladder cancer (GBC) is a rare malignancy in the Nordic countries and no common Nordic treatment guidelines exist. This study aimed to characterize the current diagnostic and treatment strategies in the Nordic countries and disclose differences in these strategies. Methods: This was a survey study with a cross-sectional questionnaire of all 19 university hospitals providing curative-intent surgery for GBC in Sweden, Norway, Denmark, and Finland. Results: In all Nordic countries except Sweden, neoadjuvant/downstaging chemotherapy was used in GBC patients. In T1b and T2, majority of the centers (15-18/19) performed extended cholecystectomy. In T3, majority of the centers (13/19) performed cholecystectomy with resection of segments 4b and 5. In T4, majority of the centers (12-14/19) chose palliative/oncological care. The centers in Sweden extended lymphadenectomy beyond the hepatoduodenal ligament, whereas all other Nordic centers usually limited lymphadenectomy to the hepatoduodenal ligament. All Nordic centers except those in Norway used adjuvant chemotherapy routinely for GBC. There were no major differences between the Nordic centers in diagnostics and follow-up. Conclusions: The surgical and oncological treatment strategies of GBC vary considerably between the Nordic centers and countries., Funding Agencies|Helsinki University Research Grants
- Published
- 2023
- Full Text
- View/download PDF
7. sj-docx-1-sjs-10.1177_14574969231181228 – Supplemental material for Practice patterns in diagnostics, staging, and management strategies of gallbladder cancer among Nordic tertiary centers
- Author
-
Takala, Sini, Lassen, Kristoffer, Søreide, Kjetil, Sparrelid, Ernesto, Angelsen, Jon-Helge, Bringeland, Erling A., Eilard, Malin S., Hemmingsson, Oskar, Isaksson, Bengt, Karjula, Heikki, Lammi, Jukka-Pekka, Larsen, Peter N., Lavonius, Maija, Lindell, Gert, Mortensen, Frank V., Mortensen, Kim, Nordin, Arno, Pless, Torsten, Sandström, Per, Sandvik, Oddvar, Vaalavuo, Yrjö, Villard, Christina, and Sallinen, Ville
- Subjects
Surgery - Abstract
Supplemental material, sj-docx-1-sjs-10.1177_14574969231181228 for Practice patterns in diagnostics, staging, and management strategies of gallbladder cancer among Nordic tertiary centers by Sini Takala, Kristoffer Lassen, Kjetil Søreide, Ernesto Sparrelid, Jon-Helge Angelsen, Erling A. Bringeland, Malin S. Eilard, Oskar Hemmingsson, Bengt Isaksson, Heikki Karjula, Jukka-Pekka Lammi, Peter N. Larsen, Maija Lavonius, Gert Lindell, Frank V. Mortensen, Kim Mortensen, Arno Nordin, Torsten Pless, Per Sandström, Oddvar Sandvik, Yrjö Vaalavuo, Christina Villard and Ville Sallinen in Scandinavian Journal of Surgery
- Published
- 2023
- Full Text
- View/download PDF
8. Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens
- Author
-
Løes, Inger Marie, Immervoll, Heike, Angelsen, Jon-Helge, Horn, Arild, Geisler, Jürgen, Busch, Christian, Lønning, Per Eystein, and Knappskog, Stian
- Published
- 2015
- Full Text
- View/download PDF
9. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
- Author
-
Les, Inger Marie, Immervoll, Heike, Sorbye, Halfdan, Angelsen, Jon-Helge, Horn, Arild, Knappskog, Stian, and Lnning, Per Eystein
- Published
- 2016
- Full Text
- View/download PDF
10. Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): Study protocol for a multicentre randomized placebo-controlled trial
- Author
-
Yaqub, Sheraz, Bjørnbeth, Bjørn Atle, Angelsen, Jon-Helge, Fristrup, Claus W., Grønbech, Jon Erik, Hemmingsson, Oskar, Isaksson, Bengt, Juel, Ingebjørg Soterud, Larsen, Peter Nørgaard, Lindell, Gert, Mortensen, Frank V., Mortensen, Kim Erlend, Rizell, Magnus, Sandström, Per, Sandvik, Oddvar Mathias, Sparrelid, Ernesto, Taflin, Helena, Taskén, Kjetil, Brudvik, Kristoffer Watten, Fretland, Åsmund Avdem, Horn, Arild, Kleive, Dyre, Labori, Knut Jørgen, Lassen, Kristoffer, Røsok, Bård Ingvald, Søreide, Jon Arne, Tholfsen, Tore, Villanger, Olaug, and Waage, Anne
- Subjects
medicine.medical_specialty ,Medicine (General) ,Colorectal cancer ,medicine.medical_treatment ,Placebo-controlled study ,Medicine (miscellaneous) ,Placebo ,Metastasis ,Study Protocol ,Liver metastases ,R5-920 ,Double-Blind Method ,Quality of life ,Acetylsalicylic acid ,Aspirin ,Secondary prevention ,Internal medicine ,medicine ,Humans ,Multicenter Studies as Topic ,Pharmacology (medical) ,Randomized Controlled Trials as Topic ,Cancer och onkologi ,business.industry ,Incidence (epidemiology) ,Liver Neoplasms ,medicine.disease ,Cancer and Oncology ,Quality of Life ,Neoplasm Recurrence, Local ,Colorectal Neoplasms ,business ,Adjuvant ,medicine.drug - Abstract
Background Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the treatment of choice although almost half of the resected patients get recurrence in the liver. Methods The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM). Up to 800 patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2 Placebo, for a period of 3 years or until disease recurrence. The patients will be recruited at all major hepatobiliary surgical units in Norway, Sweden and Denmark and have follow-up according to standard of care and the National Guidelines. Discussion The ASAC trial will be the first clinical interventional trial to assess the potential beneficial role of ASA in recurrence of CRCLM and survival. ASA is an inexpensive, well-tolerated and easily accessible drug that will be highly potential as adjuvant drug in secondary prevention of CRCLM if the study shows a beneficial effect. We will also determine the effect of ASA as adjuvant treatment on Health-Related Quality of Life and the cost-effectiveness. Trial registration ClinicalTrials.gov NCT03326791. Registered on 31 October 2017.
- Published
- 2021
11. Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): Study protocol for a multicentre randomized placebo-controlled trial
- Author
-
Yaqub, Sheraz, primary, Bjørnbeth, Bjørn Atle, additional, Angelsen, Jon-Helge, additional, Fristrup, Claus Wilki, additional, Grønbech, Jon Erik, additional, Hemmingsson, Oskar, additional, Isaksson, Bengt, additional, Juel, Ingebjørg Soterud, additional, Larsen, Peter Nørgaard, additional, Lindell, Gert, additional, Mortensen, Frank Viborg, additional, Mortensen, Kim Erlend, additional, Rizell, Magnus, additional, Sandström, Per, additional, Sandvik, Oddvar Mathias, additional, Sparrelid, Ernesto, additional, Taflin, Helena, additional, and Taskén, Kjetil, additional
- Published
- 2021
- Full Text
- View/download PDF
12. Resection rates and predictors of survival after surgery for colorectal liver metastases
- Author
-
Angelsen, Jon-Helge
- Abstract
Introduction: Occurrence of liver metastases is common following colorectal cancer (CRC), and resection is the only option with a potential for cure offered to a minor part of these patients. During the last decades there have been major improvements in the oncosurgical treatment, along with expansions in inclusion criteria for surgery. The majority of the patients will unfortunately experience post-resection recurrence. Divergent results have been presented regarding the need of clear resection margins (RMs) to accomplish an optimal outcome. Data on national resection rates in patients with CLM are sparse. Aim of the thesis: I: To study RMs and the correlation with local recurrence (LR) pattern, time to recurrence (TTR) and overall survival (OS) in patients resected for CLM. II: To study patterns of recurrence, and post-recurrence survival (PRS) according to sites of recurrence following resection for CLM. III: To study resection rates in patients diagnosed with CLM in Norway, focusing on characteristics like age, geographical regions and primary tumour. Methods: Paper I and II are based on a combined retrospective (1998-2008) and prospective (2009-2012) retrieved database of consecutive patients treated with resection for CLM at Haukeland University Hospital. Paper III is based on synchronized data from the Norwegian Patient Registry (NPR) and the Cancer Registry of Norway (CRN) where patients with a diagnosis of CRC (ICD-10: C18-20) and liver metastases (C78.7) were enrolled (2011-2013). Cumulative resection rates (CRR) following CLM were retrieved from any registration of hepatic resection (NCSP: JJB) in the data set. TTR, OS and CRR (paper I-III) were obtained using Kaplan Meier method with Log-rank test (univariate) and COX regression analysis (multivariate). All the studies were accepted by the Regional Committee for Medical and Health Research Ethics (REKVest). Results: A total of 242, 311 and 2960 patients were enrolled in paper I, II and III, respectively. In paper I the patients were grouped according to the width of the resection margins
- Published
- 2017
13. Overlevelse etter reseksjon av kolorektale levermetastaser
- Author
-
Angelsen, Jon-Helge, primary
- Published
- 2018
- Full Text
- View/download PDF
14. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
- Author
-
Løes, Inger Marie, Immervoll, Heike, Sorbye, Halfdan, Angelsen, Jon‐Helge, Horn, Arild, Knappskog, Stian, and Lønning, Per Eystein
- Subjects
Male ,Proto-Oncogene Proteins B-raf ,endocrine system diseases ,DNA Mutational Analysis ,colorectal cancer ,Kaplan-Meier Estimate ,chemotherapy ,Proto-Oncogene Proteins p21(ras) ,Molecular Cancer Biology ,Genetic Heterogeneity ,Phosphatidylinositol 3-Kinases ,Mutation Rate ,Hepatectomy ,Humans ,neoplasms ,Liver Neoplasms ,mutations ,Prognosis ,Combined Modality Therapy ,digestive system diseases ,Treatment Outcome ,Mutation ,Female ,heterogeneity ,Tumor Suppressor Protein p53 ,Colorectal Neoplasms ,Tomography, X-Ray Computed ,liver metastases - Abstract
We determined prognostic impact of KRAS, BRAF, PIK3CA and TP53 mutation status and mutation heterogeneity among 164 colorectal cancer (CRC) patients undergoing liver resections for metastatic disease. Mutation status was determined by Sanger sequencing of a total of 422 metastatic deposits. In univariate analysis, KRAS (33.5%), BRAF (6.1%) and PIK3CA (13.4%) mutations each predicted reduced median time to relapse (TTR) (7 vs. 22, 3 vs. 16 and 4 vs. 17 months; p, What's new? Preliminary evidence suggests that poor outcome after liver resection in metastatic colorectal cancer (CRC) is predicted by mutations in KRAS and BRAF and by intra‐individual heterogeneity involving copy number alterations that vary from one metastatic lesion to the next. Little is known, however, about the clinical implications of intra‐individual mutation heterogeneity in CRC. Here, in a comparison of KRAS and BRAF wild‐type status, mutational homogeneity, and mutational heterogeneity, mutation heterogeneity was found to be the strongest predict or of reduced disease‐specific survival following liver resection in metastatic CRC. Knowledge of intra‐individual mutation heterogeneity in KRAS and BRAF in CRC could facilitate therapeutic decisions.
- Published
- 2016
15. Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
- Author
-
Angelsen, Jon-Helge, Viste, Asgaut, Løes, Inger Marie, Eide, Geir Egil, Hoem, Dag, Sorbye, Halfdan, and Horn, Arild
- Subjects
Perioperative chemotherapy ,Oncology ,Surgery ,Overall survival ,Post-recurrence survival ,Sites of recurrence ,Resection colorectal liver metastases ,Time to recurrence - Abstract
Background: Despite progress in resection for colorectal liver metastases (CLM), the majority of patients experience recurrence. We aimed to evaluate factors influencing time to recurrence (TTR), treatment and post-recurrence survival (PRS) related to site of recurrence. Methods: This is a retrospective population-based cohort study (1998–2012) of consecutive patients without extrahepatic disease treated with resection for CLM in a referral centre. Results: A total of 311 patients underwent resection for CLM. After a median follow-up of 4.2 years (range 1.2–15.2), 209 (67.4 %) patients developed recurrence, hepatic 90, extrahepatic 59 and both 60. Median TTR was 14.0 months, and 5-year recurrence-free status was 25.7 %. Five- and 10-year overall survival (OS) was 38.8 and 22.0 %, respectively. Median OS was 45 months. A multivariate analysis displayed synchronous disease (hazard ratio (HR) 1.50), American Society of Anaesthesiologists (ASA) score (HR 1.40), increasing number (HR 1.24) and size of metastases (HR 1.08) to shorten TTR (all p
- Published
- 2015
16. Percutaneous cholecystostomy in acutecholecystitis; a retrospective analysis of a largeseries of 104 patients
- Author
-
Viste, Asgaut, Jensen, Dag Kjartan, Angelsen, Jon-Helge, and Hoem, Dag
- Subjects
Complications ,Cholecystitis ,Cholecystostomy ,Percutaneous - Abstract
Background: The purpose of this study was to evaluate the clinical course and possible benefit of a percutaneous cholecystostomy in patients with acute cholecystitis. Methods: Retrospective study of 104 patients with severe cholecystitis or cholecystitis not responding to antibiotic therapy treated with percutaneous drainage of the gall bladder (PC) during the period 2007 – 2013. Primary outcome was relief of cholecystitis, complications following the procedure and need for later cholecystectomy. Results: There were 57 men and 47 women with a median age of 73,5 years (range 22 – 96). 43% of the patients were ASA III or IV and 91% had cholecystitis Grade 2 or 3. About 60% of the patients had severe comorbidity (cardiovascular disease or active cancer). Drain insertion was successful in all but one patient and complications were mild, apart from two patients that needed percutaneous drainage of intraabdominal fluid collection due to bile leakage. The drain was left in place for 1 – 75 days (median 6,5). When evaluated clinically and by blood tests (CRP and white blood cell counts) we found resolution of symptoms in 101 patients (97,2%), whereas 2 patients had no obvious effect of drainage. Four patients died within 30 days, no deaths were related to the drainage procedure. Follow-up after drainage was median 12 months (range 0 – 78). During that time cholecystectomy was performed in 30 patients and 24 patients had died. Following cholecystectomy, two had died, both from cancer and more than one year after the operation. Conclusion: Patients with acute cholecystitis were promptly relieved from their symptoms following PC. There were only minor complications following the procedure and only about 30% of the patients had a later cholecystectomy. publishedVersion
- Published
- 2015
17. Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection
- Author
-
Sveen, Anita, primary, Løes, Inger Marie, additional, Alagaratnam, Sharmini, additional, Nilsen, Gro, additional, Høland, Maren, additional, Lingjærde, Ole Christian, additional, Sorbye, Halfdan, additional, Berg, Kaja Christine Graue, additional, Horn, Arild, additional, Angelsen, Jon-Helge, additional, Knappskog, Stian, additional, Lønning, Per Eystein, additional, and Lothe, Ragnhild A., additional
- Published
- 2016
- Full Text
- View/download PDF
18. Impact ofKRAS,BRAF,PIK3CA,TP5 3status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
- Author
-
Løes, Inger Marie, primary, Immervoll, Heike, additional, Sorbye, Halfdan, additional, Angelsen, Jon‐Helge, additional, Horn, Arild, additional, Knappskog, Stian, additional, and Lønning, Per Eystein, additional
- Published
- 2016
- Full Text
- View/download PDF
19. Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer.
- Author
-
Sveen, Anita, primary, Loes, Inger Marie, additional, Alagaratnam, Sharmini, additional, Nilsen, Gro, additional, Høland, Maren, additional, Lingjaerde, Ole Christian, additional, Sorbye, Halfdan, additional, Berg, Kaja Christine Graue, additional, Horn, Arild, additional, Angelsen, Jon-Helge, additional, Knappskog, Stian, additional, Lonning, Per Eystein, additional, and Lothe, Ragnhild A, additional
- Published
- 2016
- Full Text
- View/download PDF
20. Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
- Author
-
Angelsen, Jon-Helge, primary, Viste, Asgaut, additional, Løes, Inger Marie, additional, Eide, Geir Egil, additional, Hoem, Dag, additional, Sorbye, Halfdan, additional, and Horn, Arild, additional
- Published
- 2015
- Full Text
- View/download PDF
21. Percutaneous cholecystostomy in acute cholecystitis; a retrospective analysis of a large series of 104 patients
- Author
-
Viste, Asgaut, primary, Jensen, Dag, additional, Angelsen, Jon Helge, additional, and Hoem, Dag, additional
- Published
- 2015
- Full Text
- View/download PDF
22. Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens
- Author
-
Løes, Inger Marie, primary, Immervoll, Heike, additional, Angelsen, Jon-Helge, additional, Horn, Arild, additional, Geisler, Jürgen, additional, Busch, Christian, additional, Lønning, Per Eystein, additional, and Knappskog, Stian, additional
- Published
- 2014
- Full Text
- View/download PDF
23. Abstract 1878: Performance comparison of BRAF V600E detection assays in malignant melanoma and colorectal cancer specimens
- Author
-
Loes, Inger Marie, primary, Immervoll, Heike, additional, Sorbye, Halfdan, additional, Angelsen, Jon-Helge, additional, Horn, Arild, additional, Lonning, Per Eystein, additional, and Knappskog, Stian, additional
- Published
- 2014
- Full Text
- View/download PDF
24. Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival
- Author
-
Angelsen, Jon-Helge, primary, Horn, Arild, additional, Eide, Geir, additional, and Viste, Asgaut, additional
- Published
- 2014
- Full Text
- View/download PDF
25. Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival
- Author
-
Angelsen, Jon-Helge, Horn, Arild, Eide, Geir Egil, and Viste, Asgaut
- Subjects
Adult ,Male ,Resection margin ,Young Adult ,Local recurrence ,Hepatectomy ,Humans ,Overall survival ,Prospective Studies ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Research ,Liver Neoplasms ,Middle Aged ,Prognosis ,Time to recurrence ,Survival Rate ,Colorectal liver metastases ,Oncology ,Preoperative chemotherapy ,Female ,Surgery ,Neoplasm Recurrence, Local ,Colorectal Neoplasms ,Follow-Up Studies - Abstract
Background: Several reports have presented conflicting results regarding the association between resection margins (RMs) and outcome after surgery for colorectal liver metastases (CLM), especially in the era of modern chemotherapy. The purpose of this study was to evaluate the impact of RMs on overall survival (OS), time to recurrence (TTR) and local recurrence (LR) status, particularly for patients treated with preoperative chemotherapy. Methods: A combined retrospective (1998 to 2008) and prospective (2008 to 2010) cohort study of consecutive patients with CLM without extrahepatic disease treated with primary resection at a medium volume centre. Results: A total of 253 patients with known R status and 242 patients with defined margin width were included in the study. Patients were stratified according to margin width; A: R1
- Full Text
- View/download PDF
26. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
- Author
-
Labori KJ, Bratlie SO, Andersson B, Angelsen JH, Biörserud C, Björnsson B, Bringeland EA, Elander N, Garresori H, Grønbech JE, Haux J, Hemmingsson O, Liljefors MG, Myklebust TÅ, Nymo LS, Peltola K, Pfeiffer P, Sallinen V, Sandström P, Sparrelid E, Stenvold H, Søreide K, Tingstedt B, Verbeke C, Öhlund D, Klint L, Dueland S, and Lassen K
- Subjects
- Humans, Irinotecan therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Oxaliplatin therapeutic use, Leucovorin adverse effects, Neoadjuvant Therapy adverse effects, Capecitabine, Gemcitabine, Fluorouracil adverse effects, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms surgery, Pancreatic Neoplasms pathology, Adenocarcinoma drug therapy, Adenocarcinoma surgery, Adenocarcinoma pathology, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal surgery
- Abstract
Background: In patients undergoing resection for pancreatic cancer, adjuvant modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improves overall survival compared with alternative chemotherapy regimens. We aimed to compare the efficacy and safety of neoadjuvant FOLFIRINOX with the standard strategy of upfront surgery in patients with resectable pancreatic ductal adenocarcinoma., Methods: NORPACT-1 was a multicentre, randomised, phase 2 trial done in 12 hospitals in Denmark, Finland, Norway, and Sweden. Eligible patients were aged 18 years or older, with a WHO performance status of 0 or 1, and had a resectable tumour of the pancreatic head radiologically strongly suspected to be pancreatic adenocarcinoma. Participants were randomly assigned (3:2 before October, 2018, and 1:1 after) to the neoadjuvant FOLFIRINOX group or upfront surgery group. Patients in the neoadjuvant FOLFIRINOX group received four neoadjuvant cycles of FOLFIRINOX (oxaliplatin 85 mg/m
2 , irinotecan 180 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 bolus then 2400 mg/m2 over 46 h on day 1 of each 14-day cycle), followed by surgery and adjuvant chemotherapy. Patients in the upfront surgery group underwent surgery and then received adjuvant chemotherapy. Initially, adjuvant chemotherapy was gemcitabine plus capecitabine (gemcitabine 1000 mg/m2 over 30 min on days 1, 8, and 15 of each 28-day cycle and capecitabine 830 mg/m2 twice daily for 3 weeks with 1 week of rest in each 28-day cycle; four cycles in the neoadjuvant FOLFIRINOX group, six cycles in the upfront surgery group). A protocol amendment was subsequently made to permit use of adjuvant modified FOLFIRINOX (oxaliplatin 85 mg/m2 , irinotecan 150 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 2400 mg/m2 over 46 h on day 1 of each 14-day cycle; eight cycles in the neoadjuvant FOLFIRINOX group, 12 cycles in the upfront surgery group). Randomisation was performed with a computerised algorithm that stratified for each participating centre and used a concealed block size of two to six. Patients, investigators, and study team members were not masked to treatment allocation. The primary endpoint was overall survival at 18 months. Analyses were done in the intention-to-treat (ITT) and per-protocol populations. Safety was assessed in all patients who were randomly assigned and received at least one cycle of neoadjuvant or adjuvant therapy. This trial is registered with ClinicalTrials.gov, NCT02919787, and EudraCT, 2015-001635-21, and is ongoing., Findings: Between Feb 8, 2017, and April 21, 2021, 77 patients were randomly assigned to receive neoadjuvant FOLFIRINOX and 63 to undergo upfront surgery. All patients were included in the ITT analysis. For the per-protocol analysis, 17 (22%) patients were excluded from the neoadjuvant FOLFIRINOX group (ten did not receive neoadjuvant therapy, four did not have pancreatic ductal adenocarcinoma, and three received another neoadjuvant regimen), and eight (13%) were excluded from the upfront surgery group (seven did not have pancreatic ductal adenocarcinoma and one did not undergo surgical exploration). 61 (79%) of 77 patients in the neoadjuvant FOLFIRINOX group received neoadjuvant therapy. The proportion of patients alive at 18 months by ITT was 60% (95% CI 49-71) in the neoadjuvant FOLFIRINOX group versus 73% (62-84) in the upfront surgery group (p=0·032), and median overall survival by ITT was 25·1 months (95% CI 17·2-34·9) versus 38·5 months (27·6-not reached; hazard ratio [HR] 1·52 [95% CI 1·00-2·33], log-rank p=0·050). The proportion of patients alive at 18 months in per-protocol analysis was 57% (95% CI 46-67) in the neoadjuvant FOLFIRINOX group versus 70% (55-83) in the upfront surgery group (p=0·14), and median overall survival in per-protocol population was 23·0 months (95% CI 16·2-34·9) versus 34·4 months (19·4-not reached; HR 1·46 [95% CI 0·99-2·17], log-rank p=0·058). In the safety population, 42 (58%) of 73 patients in the neoadjuvant FOLFIRINOX group and 19 (40%) of 47 patients in the upfront surgery group had at least one grade 3 or worse adverse event. 63 (82%) of 77 patients in the neoadjuvant group and 56 (89%) of 63 patients in the upfront surgery group had resection (p=0·24). One sudden death of unknown cause and one COVID-19-related death occurred after the first cycle of neoadjuvant FOLFIRINOX. Adjuvant chemotherapy was initiated in 51 (86%) of 59 patients with resected pancreatic ductal adenocarcinoma in the neoadjuvant FOLFIRINOX group and 44 (90%) of 49 patients with resected pancreatic ductal adenocarcinoma in the upfront surgery group (p=0·56). Adjuvant modified FOLFIRINOX was given to 13 (25%) patients in the neoadjuvant FOLFIRINOX group and 19 (43%) patients in the upfront surgery group. During adjuvant chemotherapy, neutropenia (11 [22%] patients in the neoadjuvant FOLFIRINOX group and five [11%] in the upfront surgery group) was the most common grade 3 or worse adverse event., Interpretation: This phase 2 trial did not show a survival benefit from neoadjuvant FOLFIRINOX in resectable pancreatic ductal adenocarcinoma compared with upfront surgery. Implementation of neoadjuvant FOLFIRINOX was challenging. Future trials on treatment sequencing in resectable pancreatic ductal adenocarcinoma should be biomarker driven., Funding: Norwegian Cancer Society, South Eastern Norwegian Health Authority, The Sjöberg Foundation, and Helsinki University Hospital Research Grants., Competing Interests: Declaration of interests HG has received honoraria from Pfizer, Amgen, and Bristol Myers Squibb. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
27. Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial.
- Author
-
Yaqub S, Bjørnbeth BA, Angelsen JH, Fristrup CW, Grønbech JE, Hemmingsson O, Isaksson B, Juel IS, Larsen PN, Lindell G, Mortensen FV, Mortensen KE, Rizell M, Sandström P, Sandvik OM, Sparrelid E, Taflin H, and Taskén K
- Subjects
- Aspirin adverse effects, Double-Blind Method, Humans, Multicenter Studies as Topic, Neoplasm Recurrence, Local prevention & control, Quality of Life, Randomized Controlled Trials as Topic, Secondary Prevention, Colorectal Neoplasms prevention & control, Liver Neoplasms drug therapy, Liver Neoplasms prevention & control
- Abstract
Background: Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the treatment of choice although almost half of the resected patients get recurrence in the liver., Methods: The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM). Up to 800 patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2 Placebo, for a period of 3 years or until disease recurrence. The patients will be recruited at all major hepatobiliary surgical units in Norway, Sweden and Denmark and have follow-up according to standard of care and the National Guidelines., Discussion: The ASAC trial will be the first clinical interventional trial to assess the potential beneficial role of ASA in recurrence of CRCLM and survival. ASA is an inexpensive, well-tolerated and easily accessible drug that will be highly potential as adjuvant drug in secondary prevention of CRCLM if the study shows a beneficial effect. We will also determine the effect of ASA as adjuvant treatment on Health-Related Quality of Life and the cost-effectiveness., Trial Registration: ClinicalTrials.gov NCT03326791 . Registered on 31 October 2017., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
28. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
- Author
-
Løes IM, Immervoll H, Sorbye H, Angelsen JH, Horn A, Knappskog S, and Lønning PE
- Subjects
- Colorectal Neoplasms diagnostic imaging, Combined Modality Therapy, DNA Mutational Analysis, Female, Hepatectomy, Humans, Kaplan-Meier Estimate, Liver Neoplasms diagnostic imaging, Liver Neoplasms mortality, Male, Mutation Rate, Prognosis, Proto-Oncogene Proteins B-raf genetics, Tomography, X-Ray Computed, Treatment Outcome, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Genetic Heterogeneity, Liver Neoplasms secondary, Liver Neoplasms therapy, Mutation, Phosphatidylinositol 3-Kinases genetics, Proto-Oncogene Proteins B-raf metabolism, Proto-Oncogene Proteins p21(ras) genetics, Tumor Suppressor Protein p53 genetics
- Abstract
We determined prognostic impact of KRAS, BRAF, PIK3CA and TP53 mutation status and mutation heterogeneity among 164 colorectal cancer (CRC) patients undergoing liver resections for metastatic disease. Mutation status was determined by Sanger sequencing of a total of 422 metastatic deposits. In univariate analysis, KRAS (33.5%), BRAF (6.1%) and PIK3CA (13.4%) mutations each predicted reduced median time to relapse (TTR) (7 vs. 22, 3 vs. 16 and 4 vs. 17 months; p < 0.001, 0.002 and 0.023, respectively). KRAS and BRAF mutations also predicted a reduced median disease-specific survival (DSS) (29 vs. 51 and 16 vs. 49 months; p <0.001 and 0.008, respectively). No effect of TP53 (60.4%) mutation status was observed. Postoperative, but not preoperative chemotherapy improved both TTR and DSS (p < 0.001 for both) with no interaction with gene mutation status. Among 94 patients harboring two or more metastatic deposits, 13 revealed mutation heterogeneity across metastatic deposits for at least one gene. Mutation heterogeneity predicted reduced median DSS compared to homogeneous mutations (18 vs. 37 months; p = 0.011 for all genes; 16 vs. 26 months; p < 0.001 analyzing BRAF or KRAS mutations separately). In multivariate analyses, KRAS or BRAF mutations consistently predicted poor TRR and DSS. Mutation heterogeneity robustly predicted DSS but not TTR, while postoperative chemotherapy improved both TTR and DSS. Our findings indicate that BRAF and KRAS mutations as well as mutation heterogeneity predict poor outcome in CRC patients subsequent to liver resections and might help guide treatment decisions., (© 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.)
- Published
- 2016
- Full Text
- View/download PDF
29. [Secretin stimulated magnetic resonance cholangiopancreatography in diseases of the biliary and pancreatic ducts].
- Author
-
Hellund JC, Geitung JT, Meo AM, Angelsen JH, Munkvik M, Trondsen E, and Buanes T
- Subjects
- Adult, Aged, Common Bile Duct Diseases diagnostic imaging, Female, Humans, Injections, Intravenous, Male, Middle Aged, Pancreatic Ducts diagnostic imaging, Radiography, Sphincter of Oddi diagnostic imaging, Bile Duct Diseases diagnostic imaging, Magnetic Resonance Imaging methods, Pancreatic Diseases diagnostic imaging, Secretin administration & dosage
- Abstract
Background: MRCP has replaced ERCP as the diagnostic tool in diseases in the biliary and pancreatic ducts. Secretin increases the secretion to ducts, and this has been reported to improve MRCP image quality., Material and Methods: We report our experience with S-MRCP in our first 20 patients. Secretin was given intravenously and images were obtained every minute for 10 minutes. These images were compared with MRCP images taken before and after secretin stimulation., Results: New information was yielded in 18 cases, i.e. information not observed in previous radiological examinations., Interpretation: In diagnostics of dysfunction of the sphincter of Oddi, the method may be useful, given the functional aspect of the procedure where increased pressure in the ducts may lead to pain. It may further improve the diagnostics of pancreatic cancer versus pancreatitis, in pancreas divisum and sclerosing cholangitis. The method is also valuable for clarifying whether there is injury to the pancreatic duct after blunt abdominal trauma. Surgical common bile duct injuries may be better assessed than with any other method. In difficult pancreatic and biliary investigations, S-MRCP seems to be a useful and complication-free supplement to existing diagnostic methods.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.